Skip to main content
. 2013 May;98(5):729–738. doi: 10.3324/haematol.2011.050187

Figure 3.

Figure 3.

In vivo effect of bortezomib on HL-60, HL-60-CIP2A (HL-60 with ectopic over-expressed CIP2A), and K562 xenograft nude mice. (A) Bortezomib decreased the size of HL-60 tumors (left), but had no anti-tumor effects on HL-60-CIP2A tumors (middle) or on K562 tumors (right). Points, mean (n = 6); bars, SE; *P<0.05. (B) Bortezomib reduced the weight of HL-60 tumors (left), but had no effect on that of HL-60-CIP2A tumors (middle) or that of K562 tumors (right). Columns, mean (n = 6); bars, SD; *P<0.05. (C) Western blot analysis of CIP2A and P-Akt in HL-60, HL-60-CIP2A and K562 tumors. (D) Body weight of xenograft mice bearing HL-60 tumors (left) and HL-60-CIP2A tumors (middle) and K562 tumors (right) during the in vivo experiment. Points, mean (n = 6); bars, SE. ).